Substipharm

Executive Summary

Substipharm is a private French healthcare group founded in 1997, headquartered in Paris, with a growing global footprint in over 100 countries and direct operations in Europe and Southeast Asia. The company specializes in the development and supply of high-quality, affordable generic medicines and vaccines, operating through dedicated pharmaceutical and biologics divisions. With a focus on cost-effective healthcare solutions, Substipharm has established itself as a fast-growing player in the generics market, leveraging its extensive distribution network and regulatory expertise. The company’s portfolio includes a range of marketed products, and its strategy emphasizes expansion into emerging markets, particularly in Southeast Asia, where demand for affordable generics is rising. As a private entity, Substipharm maintains flexibility in its business decisions, allowing it to adapt quickly to market opportunities and regulatory changes.

Upcoming Catalysts (preview)

• Q2 2026Expansion of biosimilar portfolio into new geographies65% success
• Q3 2026Launch of a high-value generic in a key therapeutic area (e.g., oncology or CNS)55% success
• Q4 2026Strategic partnership or acquisition to strengthen presence in Southeast Asia50% success